论文部分内容阅读
基质金属蛋白酶2(MMP-2)是基质金属蛋白酶家族(MMPs)的重要成员,可通过高效降解细胞外基质参与充血性心力衰竭(CHF)过程中的左心室重构。CHF时MMP-2表达升高并存在与组织抑制因子失衡,因此,MMP-2与CHF的发生发展密切相关。检测MMP-2可能对判断CHF病情程度及预后具有预测作用,抑制MMP-2表达和活性有望成为治疗CHF的新策略。
Matrix metalloproteinase 2 (MMP-2) is an important member of the matrix metalloproteinases (MMPs) and may participate in left ventricular remodeling during congestive heart failure (CHF) by efficiently degrading the extracellular matrix. CHF, the expression of MMP-2 is increased and imbalance exists with tissue inhibitors, therefore, MMP-2 and CHF are closely related to the occurrence and development. Detection of MMP-2 may play a predictive role in judging the severity and prognosis of CHF. Inhibition of MMP-2 expression and activity is expected to become a new strategy for the treatment of CHF.